Ann: Race releases complete cardio-protection data & video, page-76

correct @Rhino1963 on average FTO is expressed in 15% of all cancers, some like AML and breast cancer are higher and others lower.

Is it coincidence that the 1981 pan-tumour Von Hoff review had ~14% of 27 cancers reduced tumour cells in vitro by >70% when tested with Bisantrene?

Also typically FTO overexpression seems to induce resistance against SoC treatments. Zantrene may be the solution.

This highlights the importance of the companion diagnostic work. If basically Zantrene works against cancers over expressing FTO then the success rate for these using precision therapy will be significant, which will make Zantrene highly desirable.